Recommended by the National Comprehensive Cancer Network® (NCCN®) as the preferred
first-line therapy for iMCD
SYLVANT® (siltuximab) is the only therapy approved by the US Food and Drug Administration (FDA) for the treatment of people with multicentric Castleman disease (MCD) who are negative for human immunodeficiency virus (HIV) and human herpesvirus‑8 (HHV‑8).
The NCCN recommends using siltuximab as the first-line treatment for idiopathic multicentric Castleman disease (iMCD). SYLVANT is backed by the largest and most robust clinical studies in iMCD to date.
The only targeted therapy approved and recommended by experts
My doctor said he could give me a drug that would target IL-6. Siltuximab does this.
– Yankee, iMCD patient
SYLVANT targets and neutralizes IL-6
Interleukin-6 (IL-6) levels can be elevated in patients with iMCD and may be a cause of some iMCD symptoms. SYLVANT works by binding directly to IL-6 to prevent it from interacting with its target receptor, which is found on immune cells. SYLVANT has been shown to resolve the commonly observed symptoms of iMCD by neutralizing the effects of IL-6.
In iMCD, excess amounts of a protein called IL-6 lead to overactivation of immune cells
Abnormal IL-6 signaling may cause a cytokine storm that can lead to fever, night sweats, and unexplained weight loss, which are symptoms of iMCD
SYLVANT was designed to target IL-6, preventing it from causing a cytokine storm and the symptoms associated with iMCD